Napabucasin-loaded PLGA nanoparticles trigger anti-HCC immune responses by metabolic reprogramming of tumor-associated macrophages
These findings demonstrated Napabucasin-PLGA NPs is a potential therapeutic candidate for HCC, and provided a new theoretical and experimental basis for further development and clinical application of Napabucasin.
Authors
- Yang Liu (ORCID: https://orcid.org/0000-0002-7720-2204)
- Xueyao Wang (ORCID: https://orcid.org/0009-0009-9386-0088)
- Zhiyue Zhang (ORCID: https://orcid.org/0000-0001-7070-2532)
- Qiuju Han (ORCID: https://orcid.org/0000-0002-6511-2308)
- Zhenwei Song (ORCID: https://orcid.org/0000-0001-8547-7462)
- Jian Zhang (ORCID: https://orcid.org/0000-0001-5106-1397)
- Hongfei Chen (ORCID: https://orcid.org/0000-0003-3159-8386)
- Huajun Zhao
- Hui Li (ORCID: https://orcid.org/0009-0005-0763-4166)
Institutions
- Shandong University (CN)
- University of Jinan (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1186/s12967-024-05917-x
- Citations
- 2
- Primary Topic
- Bioactive Compounds and Antitumor Agents
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- Shandong University
- National Natural Science Foundation of China
- National Key Research and Development Program of China